Remus Pharmaceuticals Ltd
REMUS
Company Profile
Business description
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
Contact
Ambli bopal Road
1101 to 1103, South Tower, One 42
Behind Ashok Vatika
Near Jayantilal Park BRTS
AhmedabadGJ380054
INDT: +91 7929999857
Sector
Healthcare
Stock type
Defensive
Industry
Medical Distribution
Fiscal Year End
31 March 2027
Employees
68
Stocks News & Analysis
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
stocks
Higher interest rates boost earnings for ASX real estate platform
Interest rates are driving a spike in property listings.
stocks
After earnings, is Palantir a buy, a sell, or fairly valued?
With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,857.70 | 8.70 | -0.10% |
| CAC 40 | 8,007.97 | 28.05 | 0.35% |
| DAX 40 | 24,136.81 | 181.88 | 0.76% |
| Dow JONES (US) | 49,693.20 | 67.36 | -0.14% |
| FTSE 100 | 10,325.35 | 60.03 | 0.58% |
| HKSE | 26,613.42 | 224.98 | 0.85% |
| NASDAQ | 26,402.34 | 314.14 | 1.20% |
| Nikkei 225 | 63,593.80 | 321.69 | 0.51% |
| NZX 50 Index | 13,007.04 | 56.02 | -0.43% |
| S&P 500 | 7,444.25 | 43.29 | 0.58% |
| S&P/ASX 200 | 8,612.50 | 2.20 | -0.03% |
| SSE Composite Index | 4,223.14 | 19.43 | -0.46% |